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ABSTRACT
Autoimmune hepatitis (AIH) is a necroinflammatory liver disease of unknown etiology. Although 
the pathogenetic mechanism of AIH is still unknown, an underlying genetic predisposition and the association 
of the disease with certain human leukocyte antigens (HLAs) have been suggested. The molecular mimicry has 
been proposed as a pathogenetic mechanism for AIH. 
The diagnosis of AIH is based on a constellation of clinical, serological, and histopathological findings. 
The International Autoimmune Hepatitis Group (IAIHG) proposed diagnosis criteria in 1993, which were revised 
in 1999. In 2008, the IAIHG decided to devise a simplified scoring system for wider applicability in routine 
clinical practice. Based on clinical and serological parameters, AIH cases have been categorized into three 
subtypes: type-1 AIH, type-2 AIH and type-3 AIH. 
The therapeutic guidelines of AIH include immunosuppressive agent with corticosteroid and usually 
in combination with azathioprine. Starting dose of prednisone monotherapy is 60 mg daily, which 
should be tapered slowly over a 1 week period to a maintenance dose of < 20 mg daily. The other 
regimen is used in combination with azathioprine, prednisone dose is started at 30 mg and tapered 
10 to 5 mg every week until a maintenance dose of 10 mg is achieved.  Azathioprine is given at the dose of 
50 mg daily. In the very few patients that do not tolerate or have significant side effects to gold standard 
therapy, alternative immunosuppressive drugs should be given. Other powerful immunosuppressive drugs 
and molecular interventions are being developed based on recent insights into pathogenic pathways, 
emerging pharmacologic agents, and new technologies.
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ABSTRAK 
Hepatitis autoimun (HAI) adalah penyakit hati akibat nekroinflamasi sel hati dengan penyebab tidak diketahui. 
Meskipun patogenesis HAI secara pasti belum diketahui, diduga HAI berkaitan dengan faktor genetik, HLA 
tertentu dan proses molekuler mimikri. 
Diagnosis HAI didasarkan pada konstelasi temuan klinis, serologi, dan histopatologi. Sejak tahun 1993, 
International Autoimmune Hepatitis Group (IAIHG) membuat kriteria diagnosis HAI, yang kemudian direvisi 
pada tahun 1999 dan pada tahun 2008 disederhanakan agar bisa diterapkan lebih luas dalam praktek klinis 
secara rutin. Berdasarkan parameter klinis dan serologi, kasus HAI dikategorikan menjadi tiga subtipe, yaitu 
HAI tipe-1, HAI tipe-2 dan HAI tipe-3.
Pedoman terapi HAI menggunakan kortikosteroid (prednison) sebagai obat imunosupresif yang umumnya 
dikombinasikan dengan azathioprine. Terapi prednison tunggal dimulai dengan dosis 60 mg/hari dan diturunkan 
pelan-pelan selama 1 minggu sampai pada dosis pemeliharaan < 20 mg/hari. Regimen lain menggunakan 
kombinasi prednison dan azathioprine 50 mg/hari, dengan dosis awal prednison 30 mg/hari, diturunkan 5 s/d 
10 mg/minggu sampai mencapai dosis pemeliharaan 10 mg/hari. Untuk pasien yang peka atau memiliki efek 
samping terhadap terapi standar emas tersebut, harus diberikan imunosupresif alternatif. Saat ini obat-obat 
imunosupresif lain dan intervensi molekuler masih dikembangkan berdasarkan perkembangan terbaru jalur 
patogenesa, farmakologis, dan teknologi.
Kata kunci: hepatitis autoimun, patogenesis, diagnosis, manajemen
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INTRODUCTION
The term autoimmune hepatitis (AIH) is used to 
describe a mostly chronic, but many times, acute 
and fulminant form of inflammatory liver disease. 
The disease entity was first described in 1950 by 
Waldenstrom, as a chronic form of hepatitis in young 
women. In 1965, it became designated by Mackay et 
al as “autoimmune hepatitis”. Since then, it has been 
known by a variety of terms, including active chronic 
hepatitis, chronic active hepatitis or autoimmune 
chronic active hepatitis and by other names such 
as chronic aggressive hepatitis, lupoid hepatitis 
and plasma cell hepatitis. In 1994, the International 
Autoimmune Hepatitis Group (IAIHG) designated 
“autoimmune hepatitis” as the most accurate and 
suitable term for such condition.1,2,3 
AIH is a generally unresolving inflammation of 
the liver of unknown cause. A working model for its 
pathogenesis postulates that environmental triggers, 
failured immune tolerance mechanisms, and genetic 
predisposition collaborate to induce a T-cell–mediated 
immune attack upon liver antigens, leading to 
progressive necroinflammatory and fibrotic process 
in the liver.4,5,6 
The diagnosis of AIH is based on histological 
abnormalities, characteristic clinical and laboratory 
findings, abnormal levels of serum globulins, and 
the presence of one or more characteristic auto-
antibodies. Female are affected more frequently than 
male (sex ratio female : male was 3.6 : 1), and the 
disease is seen in all ethnic groups and at all ages. The 
AIH has an incidence of 1 to 2 per 100,000 persons per 
year and it has a prevalence of 11 to 17 per 100,000 
persons per year.7,8,9 There has been no definite data 
reported on the incidence of AIH in Indonesia.
It is important to distinguish AIH from other forms 
of chronic hepatitis since a high percentage of cases may 
respond to anti-inflammatory or immunosuppressive 
therapy, or both. Although appropriate management 
can prolong survival, improve the quality of life, and 
avoid the need for liver transplantation, but there are 
considerable therapeutic challenges remain in the 
treatment of this disorder.10 The objective of our review 
is to focus on the management of AIH.
ETIOLOGY AND PATHOGENESIS
The liver is a unique anatomical and immunological 
site,  in which antigen-rich blood from the 
gastrointestinal tract is pressed through a network of 
sinusoids and scanned by antigen presenting cells and 
lymphocytes. The liver’s lymphocyte population is 
selectively enriched in natural killer and natural killer 
T-cells which play critical roles in first line immune 
defense against invading pathogens, modulation of 
liver injury and recruitment of circulating lymphocytes. 
Circulating lymphocytes that come in close contact to 
antigens are displayed by endothelial cells, Kupffer 
cells and liver resident dendritic cells in the sinusoids. 
Circulating lymphocytes can also have direct contact 
with hepatocytes because the sinusoidal endothelium 
is fenestrated and lack of basement membrane. This 
unique anatomy of the liver may facilitate direct or 
indirect priming of lymphocytes, modulate the immune 
response to hepatotrophic pathogens and contributes 
to some of the unique immunological properties of 
this organ, particularly its capacity to induce antigen-
specific tolerance.11 
The pathogenetic mechanism of AIH is still 
unknown, but the most common theory of the 
mechanism of inflammatory injury in AIH postulates 
that an environmental agent, either a drug or a virus or 
another agent seems to trigger a T-cell mediated cascade 
directed against liver antigens in genetically predisposed 
individuals. Various mechanisms have recently been 
identified. The most important and convincing seems to 
be the model of autoreactive T-cells. Immune reactions 
against host liver antigens are believed to be the major 
pathogenic mechanism of AIH.4,5 
An underlying genetic predisposition has been 
suggested because of the fact that patients are 
predominantly female and the association of the 
disease with certain human leukocyte antigens (HLAs). 
HLA genes reside in the major histocompatibility 
complex (MHC), which is located on the short arm 
of chromosome 6. The MHC is a genetic system with 
extensive polymorphism. Although multiple genes 
are probably involved, HLA genes appear to play 
the dominant role in predisposition to AIH.4,6
Molecular mimicry has also been proposed as 
a pathogenetic mechanism for AIH. In molecular 
mimicry, multiple antigens such as hepatitis C virus, 
cytomegalovirus, and herpes simplex type 1 virus, 
with the same or similar epitopes on the recombinant 
CYP2D6 can activate CD4+ T-cells because of 
incomplete specificity of T-cell antigen receptors. 
It has been recognize as the break self-tolerance. Such 
activation may lead to expansion of liver-infiltrating 
cytotoxic T-cells that may cause liver injury and 
develop the antigen-sensitized plasma cells that 
produce autoantibodies. Humoral cross-reactivity 
or the cross-reacting antibodies has been described 
in autoimmune conditions; however, cellular cross-
reactivity that includes cross-reacting lymphocytes 
has been difficult to demonstrate.4,6,12 
DIAGNOSTIC CRITERIA
AIH is one of chronic liver diseases resulting from 
dysregulated immune mechanism which has not yet 
clearly defined. The diagnosis is based on a constellation 
of clinical, serological, and histopathological findings. 
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- Type-2 AIH, seen more frequently the pediatric 
population. It is often associated with severe 
clinical disease and positive anti-LKM in the 
serum and the patients are usually negative for 
ANA or SMA. Type-2 AIH in adults may progress 
to cirrhosis more frequently than type-1 AIH (82% 
vs. 43% within 3 years). 
- Type-3 AIH is represented in patients with 
antibodies to soluble liver antigen (SLA) or 
antibodies against the liver pancreas antigen (LP). 
The antibodies are designated together as SLA/
LP. Both antibodies, especially the former one, 
are also found in patients with the classic form of 
AIH; therefore, patients with type 3 AIH are now 
considered as the type 1 AIH.
Liver biopsy plays an important role in diagnosis 
and management of AIH patient. Histologically, portal 
and periportal chronic inflammation with prominent 
plasma cells is typically found in liver biopsies. 
The amount of inflammation and number of plasma 
cells can be quite variable. In clinically severe cases, 
the periportal lymphoplasmacytic activity or the 
interface hepatitis or piece-meal necrosis may be 
very pronounced. Presence of portal plasma cells in 
liver biopsies, from patients under therapy-induced 
remission, was found to be a predictor of relapse 
following treatment withdrawal. The plasma cells 
also may indicate persistence of immune response. 
The presence of interface hepatitis on the follow-up 
tissue examination justifies the continuation of therapy 
for an additional 6 month before reconsidering drug 
withdrawal. Full resolution of liver tests and tissue is 
an ideal treatment end point, but it may be achievable 
in only 40% of patients.9,19 
THERAPEUTIC MANAGEMENT 
The principle of therapy for chronic inflammatory 
liver diseases is the removal of causal agents. For 
autoimmune liver diseases, however, total removal 
of causal agents and immune cells is impossible. 
Therefore, autoimmune liver diseases are presently 
treated by suppression of the immune response. AIH is 
characteristically responsive to corticosteroids, which 
are often used in combination with azathioprine to 
obtain a steroid-sparing effect.20 
Indication of Treatment
The absolute indications for treatment are based 
on the original studies of symptomatic patients. They 
are: (1) serum aspartate aminotransferase (AST) levels 
greater than ten-fold upper limit of normal range; 
(2) serum AST levels that greater than five-fold upper 
limit of normal in combination with a serum γ-globulin 
levels that are two-fold the upper limit of normal; 
(3) histological evidence of bridging or multiacinar 
Clinically, it is more often encountered in female than 
male. Seropositivity for auto-antibodies is found in 
most cases. Histologically, the typical findings consist 
of periportal, portal, and lobular chronic inflammation 
with prominent plasma cells.9 
Based on combination of clinical and laboratory 
parameter with both positive and negative weight, IAIHG 
devised a scoring system in 1993.13 The sum of numerical 
score given to each of these parameters is useful in 
predicting the definite or possible diagnosis of AIH in 
a given patient. The system was modified in 1999 and 
has proven to be useful for both diagnostic and research 
purposes.14 It is highly sensitive for the diagnosis of AIH 
with a diagnostic accuracy close to 90%. The negative 
scores given to biliary marker/findings provide help in 
excluding AIH for patients with biliary diseases who may 
have some overlapping features.9 
Hennes et al decided to devise a simplified scoring 
system for wider applicability in routine clinical 
practice based on the data of patients with well-
established diagnoses. The simplified scoring system 
assesses only 4 factors (Table 1), i.e. the nature and 
level of autoantibody production evaluated based 
on assays of indirect immunofluorescence, serum 
immunoglobulin (Ig) G concentration, the presence 
of typical or compatible histological features, and 
the absence of viral markers.15 The simplified scoring 
system detects fewer cases of AIH than the original 
system. It has lower sensitivity (95% vs. 100%), 
but demonstrates higher specificity (90% vs. 73%) 
and accuracy (92% vs. 82%). The simplified scoring 
system is useful in excluding AIH for patients with 
other conditions and concurrent immune features.16,17 
Table 1. Simplified criteria for the diagnosis of autoimmune 
hepatitis15
Variable Cut off Points
Autoantibodies
ANA or SMA positive ≥ 1: 40 + 1
ANA or SMA positive ≥ 1: 80 + 2
Anti-LKM1 positive ≥ 1:40 + 2
Anti-SLA Positive + 2
IgG level > Upper limit of normal + 1
>1.1 upper limit of normal + 2
Liver histology Compatible with AIH
Typical of AIH
+ 1
+ 2
Absence of viral hepatitis Yes +2
AIH: autoimmune hepatitis; Interpretation of aggregate score ≥ 6 points: probable AIH; ≥ 7 
points: definite AIH; ANA: anti-nuclear antibody, SMA: smooth muscle antibody, anti-LKM1: 
antibodies to liver kidney microsome type 1; anti-SLA: antibodies to soluble liver antigen
Based on clinical and serological parameters, AIH 
cases have been categorized into three subtypes:9,18 
- Type-1 AIH is the most common (80%) form of 
the diseases. It has been seen mostly (78%) in 
adult female. Serologically, it is characterized by 
the presence of high-titer anti-nuclear antibody 
(ANA) and/or anti-smooth muscle (SMA).
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necrosis; (4) incapacitating symptoms. These criteria 
represent a severe end of the disease spectrum, in which 
untreated patients would have a mortality of 40% 
within six months and their ten-years survival would 
only about 27%.21,22 
Immunosuppressive therapy with corticosteroids, 
usually in combination with azathioprine is considered 
as the gold standard to induce and maintain remission. 
These two treatment regimens are equally effective 
in severe AIH (Table 2). Prednisone alone at the dose 
of 60 mg daily or a lower dose of prednisone (30 mg 
daily) in conjunction with 50 mg azathioprine is usually 
used in the United States or it may be administered at 
dose of 1-2 mg/kg body weight daily, which is widely 
used in Europe. Prednisone may be tapered down to an 
individual level sufficient to maintain a remission from 
20 mg daily onward. Reduction should be done by 5 
mg every week until 10 mg/day are achieved and even 
further reduction by 2.5 mg/week have been considered 
up to 5 mg daily. The maintenance regimen is then 
continued until resolution of the disease, treatment 
failure, or drug-intolerance.22 
The combination regimen is appropriate in 
patients who will be treated continuously for at least 
6 months or who are at increased risk for drug-related 
complications, including postmenopausal female and 
individuals with emotional instability, osteoporosis, 
brittle diabetes, labile hypertension, or obesity. 
Patients receiving prednisone should undergo eye 
examinations for cataracts and glaucoma periodically 
during treatment, and those receiving azathioprine in 
any dose should be monitored at 6 month intervals for 
leukopenia and thrombocytopenia.22 
Corticosteroid therapy is established as an effective 
treatment for AIH. It induces clinical, laboratory and 
histological remission in 80% of patients within 3 
years; the 10- and 20-years life expectancies of treated 
patients exceed 80%; hepatic fibrosis is reduced or 
prevented in 79% cases; and variceal hemorrhage, 
death from hepatic failure, and deteriorations 
warranting liver transplantation occur in less than 5%. 
These successes are tempered by the development of 
severe treatment-related side effects in 13% cases, 
treatment failure in 9%, incomplete response in 13%, 
and relapse after drug withdrawal in 50%-86%.19 
In the very few patients that do not tolerate or have 
significant side effects to standard therapy, alternative 
immunosuppressive treatment should be given. 
Endpoint of Treatment
The therapeutic goal should be complete normalization 
of transaminases because progression to liver cirrhosis 
may occur in patients with residual inflammatory activity 
within the liver. Conventional therapy in adults is continued 
until remission, treatment failure, incomplete response, or 
drug toxicity (Table 3).22 Despite some patients remain 
Table 2. Immunosuppresive treatment regimens for adults in 
autoimmune hepatitis21
Monotheraphy Combination therapy
Prednisone only* 
(mg/day)
Prednisone* 
(mg/day)
Azathioprine
USA  
(mg/day)
EU 
(mg/kg/day)
Week-1 60 30 50 1-2
Week-2 40 20 50 1-2
Week-3 30 15 50 1-2
Week-4 30 15 50 1-2
Maintenance 
until endpoint 20 and below 10 50 1-2
Table 3. The endpoints of initial immunosuppressive treatment and courses of action in autoimmune hepatitis22
Treatment endpoint Criteria     Courses of action
Remission Disappearance of symptoms, normal serum 
aminotransferases, bilirubin and γ -globulin 
levels, normal hepatic tissue or inactive 
cirrhosis
− Gradual withdrawal of prednisone over 6-week period
− Serum AST or ALT, total bilirubin, and c-globulin 
levels determined at 3 week intervals during and 
for 3 months
after drug withdrawal
− Repeat laboratory assessments thereafter every 
6 months for at least 1 year and then every year 
life-long
Treatment failure − Worsening clinical, laboratory and 
histological features despite compliance 
with therapy
− Development of jaundice ascites or 
hepatic encephalopathy
− Prednisone, 60 mg daily, or prednisone, 30 mg daily, 
and azathioprine, 150 mg daily, for at least 1 month
− Dose reduction of prednisone by 10 mg and 
azathioprine by 50 mg for each month of improvement 
until standard treatment doses are achieved
Incomplete response Some or no improvement in clinical, labora-
tory, and histological features despite com-
pliance with therapy after 2-3 years
− Reduction in doses of prednisone by 2.5 mg/month 
until lowest level possible (≤ 10 mg daily) to prevent 
worsening of serum AST or ALT abnormalities
− Indefinite azathioprine therapy (2 mg/kg daily) as 
an alternative treatment if corticosteroid intolerance
Drug toxicity Development of intolerable cosmetic chang-
es, symptomatic osteopenia, emotional 
instability, poorly controlled hypertension, 
brittle diabetes or progressive cytopenia
− Reduction in dose or discontinuation of offending 
drug
− Maintenance on tolerated drug in adjusted dose
AST: aspartate aminotransferase; ALT: alanine aminotransferase
* Prednisolone can be used in place of prednisone in equivalent doses; USA: United States 
of America; EU: European Union
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in remission after drug treatment is withdrawn, most 
patients require long-term maintenance therapy. Albeit 
there is only scarce evidence for how long maintenance 
therapy should be given, it has been proposed that 
patients should be in stable remission for at least 
4 years before withdrawal of immunosuppressive 
therapy can be considered. However, patients who 
are positive for anti-LKM1 (type 2 AIH) should be 
treated with life-long immunosuppressive treatment, 
which can only be stopped in patients with ANA and 
SMA-positive AIH (type 1 AIH).23 
Non-classical Phenotypes 
The phenotypes that satisfy the definition of AIH 
but are outside the boundaries of classical disease 
have acute severe presentations, few or no symptoms 
(known as asymptomatic AIH), atypical histological 
findings, absent or variant serological markers, 
concurrent cholangiographic changes, male gender, 
and non-Caucasian backgrounds.24 
In the acute severe or the fulminant presentation of 
AIH, corticosteroid therapy is effective in 36-100% 
patients. The response to corticosteroid therapy should 
be evident quickly, and the failure of any laboratory 
test of liver inflammation to improve within 2 weeks 
in a patient with acute severe disease is a justification 
for considering liver transplantation.19,24
AIH may be asymptomatic in 25-34% of patients 
and 25-85% of individuals can be classified as having 
mild disease by clinical, laboratory and histological 
findings. Asymptomatic patients are typically men, 
and they have lower serum AST levels at presentation 
than symptomatic patients. Histological features are 
similar between symptomatic and asymptomatic 
patients, including the occurrence of cirrhosis, and 26-
70% of asymptomatic patients become symptomatic 
during follow-up. Spontaneous resolution is possible, 
but cirrhosis develops in 49% of untreated patients 
within 15 years. Until randomized clinical trials are 
performed comparing treatment against no treatment, 
the management strategy in patients with mild AIH 
should lean toward conventional therapy.19,24 
The histological hallmark of AIH is interface 
hepatitis, but other histological findings are compatible 
with the disease. Centrilobular zone 3 necrosis is 
probably an early form of AIH that is detected mainly 
in patients with an acute onset. Concurrent biliary 
changes, including isolated destructive cholangitis, 
may also be found in patients with otherwise classical 
AIH. Fatty changes may also be present at accession 
or after corticosteroid therapy. These non-classical 
findings should not alter the diagnosis or the treatment 
strategy.24 
Seronegative patients with AIH constitute an 
“autoantibody-negative AIH”. They may have escaped 
detection by testing for the conventional autoantibodies, 
or their serological signature may be undiscovered or 
may express conventional autoantibodies later in the 
course of their disease. Confidence in the diagnosis 
of autoantibody-negative AIH can be strengthened 
by applying the comprehensive scoring system of 
the IAIHG. Once the diagnosis has been made by the 
exclusion of other conditions that it might resemble, 
corticosteroid treatment should be started with 
regimens identical to those used in classical AIH. 
Treatment should not be extended beyond 3 months if 
there has been no improvement, and the accuracy of the 
original diagnosis and the legitimacy of the treatment 
regimen should be reassessed if the disease worsens in 
spite of compliance with the medication schedule.19,24 
The overlap syndromes are important because 
they are common, occur in 18% of adults with 
autoimmune liver disease and they can respond poorly 
to corticosteroid therapy. The variant syndromes should 
be suspected when patients with AIH manifest clinical, 
laboratory or histological features of cholestasis 
or respond poorly to conventional corticosteroid 
therapy. The serum alkaline phosphatase level is 
useful in distinguishing classical AIH from its overlap 
syndromes with primary biliary cirrhosis (PBC) 
and primary sclerosing cholangit is  (PSC). 
Serum alkaline phosphatase levels more than 
four-fold higher than the upper limit of the normal 
(ULN) do not occur in classical AIH, and the presence 
of an abnormality of this degree in a patient with other 
features of AIH compels a search for underlying PBC 
or PSC.19,24 
Management of the overlap syndromes is empirical 
and based on the predominant manifestations of the 
disease. Adults with AIH and features of PBC who have 
serum alkaline phosphatase levels less than two-fold 
higher than ULN can be treated with corticosteroids. 
Adults with higher serum alkaline phosphatase levels and 
those with florid duct lesions on histological examination 
are candidates for treatment with corticosteroids 
and ursodeoxycholic acid. Adults with AIH and 
PSC are commonly given a trial of prednisone and 
ursodeoxycholic acid, but in adults with mainly hepatitis 
features, corticosteroid therapy alone may be beneficial.19 
Alternative Drug Therapies for Sub Optimal 
Responses
Treatment options have increased in AIH as new 
drugs with targeted immunosuppressive actions have 
been used empirically. None of these treatments has been 
incorporated into standard management algorithms, 
but they constitute an evolving armamentarium that 
promises to improve outcomes by either interrupting 
critical pathogenic pathways or eliminating intolerances 
to the current medications.24 
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The calcineurin inhibitors (cyclosporine and 
tacrolimus) have been used as frontline and salvage 
therapies in children and adults with AIH, and 
multiple small clinical experiences have supported 
their efficacy and tolerance. The purine antagonists 
(6-mercaptopurine and mycophenolate mofetil) have 
also been proven effective in some patients refractory 
to conventional corticosteroid regimens.22,24 
Budesonide is a third generation corticosteroid that 
has been used empirically as frontline and salvage 
therapy in AIH. Its high first-pass clearance by the liver 
and its breakdown to inactive metabolites promised to 
improve efficacy and safety compared to conventional 
corticosteroid regimens. Budesonide in combination 
with azathioprine has been found to be superior to 
prednisolone and azathioprine in normalizing the serum 
ALT level and reducing the frequency of steroid-related 
side effects after 6 months of treatment. Budesonide 
has not been effective as a salvage therapy in patients 
with severe disease on long-standing corticosteroid 
treatment. Moreover, the corticosteroid-induced side 
effects are still possible, especially in patients who 
have been treated previously with prednisone or who 
have cirrhosis.24 
Various other drugs (cyclophosphamide, 
methotrexate, rapamycin, rituximab, intravenous 
immunoglobulin, deflazacort, and ursodeoxycholic 
acid) have been proposed for use in AIH, and their 
number reflects the need for better salvage therapies 
in the treatment of AIH. Prospective and scientifically 
rigorous collaborative studies are needed to expand 
the therapeutic repertoire and comprehensive analyses 
are required to demonstrate that these incremental 
improvements in outcome are cost-effective.22,24 
Promising Targeted Molecular and Cellular Therapies
Cellular and molecular therapies are being developed 
to preserve adaptive immune defenses, reduce treatment-
related complications, ensure prompt onset of action, 
and allow tight regulation of the duration and intensity 
of the immunosuppressive effect. These interventions 
are feasible because of improved understanding on the 
critical pathogenic pathways of AIH.12 
Site-specific molecular inventions, including 
antigen-blocking synthetic peptides, cytokine 
manipulations, T-cell vaccination, and oral tolerance 
regimens, become feasible when the critical pathogenic 
mechanisms of the disease are clarified, and confident 
animal models of the human disease are developed. 
Mesenchymal stem cells from human bone marrow 
that can differentiate into functional hepatocytes have 
the potential to rescue individuals from liver failure, 
reduce reliance on whole organ transplantation, and 
obviate the complications of whole organ rejection 
and drug toxicity.12,24 
CONCLUSION
AIH must be considered in all individuals with 
acute and chronic hepatitis of undetermined cause. 
A diagnostic scoring system that was promulgated 
mainly as a research tool in 1993 had been revised in 
1999 to exclude cholestatic syndromes. A simplified 
diagnostic scoring system was added in 2008 to ease 
clinical application, and both systems can now be 
exploited to strengthen the diagnosis in difficult cases.
Optimization of corticosteroid regimens may 
increase treatment-free intervals, protect against 
overtreatment, and identify candidates for other 
therapies. The non-classical manifestations do not 
alter the management strategy, but they require prompt 
recognition and confident diagnosis. The new drugs 
with targeted immunosuppressive actions have been 
used empirically, and budesonide promises to be more 
effective and safer than current agents in treatment-
naive patients. Other powerful immunosuppressive 
drugs and molecular interventions are being developed 
based on recent insights into pathogenic pathways, 
emerging pharmacologic agents, and new technologies.
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